Search
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin
Methylcellulose
go.drugbank.com/drugs/DB11228ApprovedInvestigationalMethyl cellulose polymer consisting of numerous linked glucose molecules used as a stabiliser, thickener and emulsifier for foodstuffs and cosmetics. … It is available under a variety of trade names as a treatment for constipation. Like cellulose, it is not digestible, not toxic, and not allergenic
Magnesium citrate
go.drugbank.com/drugs/DB11110ApprovedInvestigational[L2831] It is also considered as an active ingredient in over-the-counter products.[L1113] … [T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.
Clove oil
go.drugbank.com/drugs/DB11338ApprovedNutraceuticalThe FDA categorizes clove oil as generally recognized as safe (GRAS) for use in dental cement or as a food additive [F108]. … Traditionally, it has been used as a flavouring spice in foods, or as a fragrance. It is also found in topical analgesics. Clove oil has shown to exert some antimicrobial activities.
Triethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigationalTriethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. … [A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and
Aflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in … biosimilars—Yesafili (aflibercept-jbvf)[L53043] and Opuviz (aflibercept-yszy)[L53038], approved in May 2024, and Ahzantive (aflibercept-mrbb)[L53048], approved in July 2024—were authorized by the FDA as
Oliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin … effects such as constipation and respiratory depression.
Fexofenadine
go.drugbank.com/drugs/DB00950ApprovedInvestigational[diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation. … for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation antihistamines, such as
Ammonia
go.drugbank.com/drugs/DB11118ApprovedInvestigationalAlthough ammonia is used as a food additive in the anhydrous form and serves as a starting material in pharmaceutical and commercial products, it is caustic and hazardous when concentrated. … Ammonia gas has been used in the clinical setting as a respiratory stimulant to prevent fainting.
Abarelix
go.drugbank.com/drugs/DB00106ApprovedWithdrawnIt is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.